---
document_datetime: 2023-09-21 19:44:55
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/daklinza-epar-all-authorised-presentations_en.pdf
document_name: daklinza-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.3501194
conversion_datetime: 2025-12-24 06:00:12.930997
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
EU/1/14/939/001

EU/1/14/939/002

EU/1/14/939/003

EU/1/14/939/004

Daklinza

Daklinza

Daklinza

Daklinza

30 mg

30 mg

60 mg

60 mg

Film-coated tablet

Film-coated tablet

Film-coated tablet

Film-coated tablet

Oral use

Oral use

Oral use

Oral use blister (PVC/

PCTFE/ Alu)

blister (PVC/

PCTFE/ Alu)

blister (PVC/

PCTFE/ Alu)

blister (PVC/

PCTFE/ Alu)

28 tablets

28 x 1 tablet

(unit dose)

28 tablets

28 x 1 tablet

(unit dose)

MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administration Immediate Packaging Pack size Medicinal product no longer authorised